Study: Progression of cardiodiabesity increases care utilization and costs
The Evernorth Research Institute’s latest cardiodiabesity report helps illustrate sites of care where preventive interventions can make the greatest financial impact.
Read MoreEvernorth Announces Industry-First Financial Guarantee For GLP-1 Spend
EncircleRx solution now includes financial predictability for health plan sponsors to help expand access for appropriate patients.
Read MoreEasing the impact of GLP-1s
With GLP-1 sales forecast to exceed $100 billion, plan sponsors need the tools to control growth and expand access.
Read MoreHow to improve specialty drug adherence for patients with inflammatory conditions
To mitigate nonadherence for inflammatory condition treatments, plan sponsors should adopt a multifaceted approach that combines clinical protocols and value-based solutions.
Read MoreLeveraging comprehensive medication reviews to manage chronic diseases
Plan sponsors can leverage pharmacists in order to improve the health of their members with chronic diseases.
Read More